NCT00102661View on ClinicalTrials.gov

Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

September 30, 2006

Study Completion Date

September 30, 2006

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Campath-1H

15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Berlex Laboratories, Inc.
All Listed Sponsors
collaborator

Berlex Laboratories, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00102661 - Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter